{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:11:27Z","timestamp":1792127487027,"version":"4.4.0"},"reference-count":119,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>IFN\u03b1 has been used to treat malignant and viral disorders for more than 25 years. Its efficacy is likely the consequence of its broad range of biologic activities, including direct effects on malignant cells, enhancement of anti-tumor immune responses, induction of proapoptotic genes, inhibition of angiogenesis, and promotion of the cycling of dormant malignant stem cells. Because of the recent development of \u201ctargeted\u201d therapies, the use of IFN has been dramatically reduced over the last decade. The increasing awareness of the multistep pathogenesis of many malignancies has suggested, however, that such an approach using target-specific agents is not universally effective. These observations have resulted in a number of recent clinical trials utilizing IFN\u03b1 in patients with chronic myeloid leukemia (CML), systemic mast cell disease, hypereosinophilic syndrome and the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) with promising outcomes. These reports provide evidence that IFN\u03b1, alone or in combination with other agents, can induce surprisingly robust molecular response rates and possibly improve survival. Although IFN\u03b1 at present remains an experimental form of therapy for patients with myeloid malignancies, these promising results suggest that it may become again an important component of the therapeutic arsenal for this group of hematologic malignancies.<\/jats:p>","DOI":"10.1182\/blood-2010-08-258772","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T04:52:46Z","timestamp":1299732766000},"page":"4706-4715","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":187,"title":["The renaissance of interferon therapy for the treatment of myeloid malignancies"],"prefix":"10.1182","volume":"117","author":[{"given":"Jean-Jacques","family":"Kiladjian","sequence":"first","affiliation":[{"name":"Centre d'Investigations Cliniques, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"Universit\u00e9 Paris Diderot\u2013Paris 7, Paris, France;"},{"name":"Inserm, CIC 9504, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111703285070400_B1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine.","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2019111703285070400_B2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/1078-0432.CCR-09-2760","article-title":"New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.","volume":"16","author":"le Coutre","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111703285070400_B3","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.3816\/CLM.2009.s.020","article-title":"Hairy cell leukemia.","volume":"9","author":"Ravandi","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"2019111703285070400_B4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"49","key":"2019111703285070400_B5","first-page":"538","article-title":"Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.","volume":"9","author":"Shao","year":"2010","journal-title":"Discov Med"},{"issue":"8","key":"2019111703285070400_B6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/07357907.2010.494322","article-title":"Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.","volume":"28","author":"Wozniak","year":"2010","journal-title":"Cancer Invest"},{"issue":"5","key":"2019111703285070400_B7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11912-010-0116-1","article-title":"Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the \u201cbest\u201d therapy?","volume":"12","author":"Agrawal","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2019111703285070400_B8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.2803","article-title":"Jekyll and Hyde: the role of the microenvironment on the progression of cancer.","volume":"223","author":"Allen","year":"2011","journal-title":"J Pathol"},{"issue":"4","key":"2019111703285070400_B9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond.","volume":"47","author":"La Rosee","year":"2010","journal-title":"Semin Hematol"},{"key":"2019111703285070400_B10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-12-380866-0.60012-5","article-title":"DNA demethylating agents and epigenetic therapy of cancer.","volume":"70","author":"Mani","year":"2010","journal-title":"Adv Genet"},{"key":"2019111703285070400_B11","first-page":"151","article-title":"Small-molecule inhibitors of the p53-MDM2 interaction.","volume":"348","author":"Vu","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"2019111703285070400_B12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jir.2005.25.511","article-title":"Review: Milstein Award lecture: interferons and cancer: where from here?","volume":"25","author":"Borden","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"10","key":"2019111703285070400_B13","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.1996.14.10.2627","article-title":"Interferons as biochemical modulators.","volume":"14","author":"Borden","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703285070400_B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2009.07747.x","article-title":"Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.","volume":"146","author":"Potenza","year":"2009","journal-title":"Br J Haematol"},{"issue":"28","key":"2019111703285070400_B15","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.R700004200","article-title":"The interferons: 50 years after their discovery, there is much more to learn.","volume":"282","author":"Pestka","year":"2007","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111703285070400_B16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling.","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2019111703285070400_B17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J Exp Med"},{"issue":"6\u20137","key":"2019111703285070400_B18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.biochi.2007.01.008","article-title":"IL-28 and IL-29: newcomers to the interferon family.","volume":"89","author":"Uze","year":"2007","journal-title":"Biochimie"},{"issue":"6607","key":"2019111703285070400_B19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/384364a0","article-title":"Dendritic cells capable of stimulating T cells in germinal centres.","volume":"384","author":"Grouard","year":"1996","journal-title":"Nature"},{"issue":"4","key":"2019111703285070400_B20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons.","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2019111703285070400_B21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/157489108786242378","article-title":"The use of interferon-gamma therapy in chronic granulomatous disease.","volume":"3","author":"Errante","year":"2008","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"24","key":"2019111703285070400_B22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM199506153322402","article-title":"Long-term treatment of osteopetrosis with recombinant human interferon gamma.","volume":"332","author":"Key","year":"1995","journal-title":"N Engl J Med"},{"issue":"28","key":"2019111703285070400_B23","doi-asserted-by":"crossref","first-page":"20053","DOI":"10.1074\/jbc.R700006200","article-title":"Type I interferon receptors: biochemistry and biological functions.","volume":"282","author":"de Weerd","year":"2007","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111703285070400_B24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri1684","article-title":"The yin and yang of type I interferon activity in bacterial infection.","volume":"5","author":"Decker","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111703285070400_B25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"issue":"8","key":"2019111703285070400_B26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0301-472X(99)00060-0","article-title":"CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors.","volume":"27","author":"Platanias","year":"1999","journal-title":"Exp Hematol"},{"issue":"2","key":"2019111703285070400_B27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","article-title":"Differential receptor subunit affinities of type I interferons govern differential signal activation.","volume":"366","author":"Jaks","year":"2007","journal-title":"J Mol Biol"},{"issue":"6","key":"2019111703285070400_B28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators\u2013a new look.","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"key":"2019111703285070400_B29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The IRF family transcription factors in immunity and oncogenesis.","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2019111703285070400_B30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2402602","article-title":"Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.","volume":"16","author":"Paquette","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2019111703285070400_B31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/08916930903510880","article-title":"Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.","volume":"43","author":"Rizza","year":"2010","journal-title":"Autoimmunity"},{"issue":"8","key":"2019111703285070400_B32","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703285070400_B33","doi-asserted-by":"crossref","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.","volume":"5","author":"Kanodia","year":"2010","journal-title":"PLoS ONE"},{"issue":"6","key":"2019111703285070400_B34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14653240802317639","article-title":"Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.","volume":"10","author":"Seggewiss","year":"2008","journal-title":"Cytotherapy"},{"issue":"2","key":"2019111703285070400_B35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2141.2000.02361.x","article-title":"Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.","volume":"111","author":"Chen","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111703285070400_B36","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.","volume":"88","author":"Molldrem","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111703285070400_B37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111703285070400_B38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"issue":"2","key":"2019111703285070400_B39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10428190400012029","article-title":"Interferon alpha and T-cell responses in chronic myeloid leukemia.","volume":"46","author":"Burchert","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111703285070400_B40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"26","key":"2019111703285070400_B41","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111703285070400_B42","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.4049\/jimmunol.177.7.4907","article-title":"An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.","volume":"177","author":"Xiong","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"2019111703285070400_B43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2006.10.006","article-title":"Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.","volume":"122","author":"Xiong","year":"2007","journal-title":"Clin Immunol"},{"issue":"4","key":"2019111703285070400_B44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"issue":"6","key":"2019111703285070400_B45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"32","key":"2019111703285070400_B46","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703285070400_B47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/ph3040994","article-title":"Antiproliferative properties of type I and type II interferon.","volume":"3","author":"Bekisz","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"2019111703285070400_B48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08916930903510963","article-title":"Interferon-alpha as angiogenesis inhibitor: learning from tumor models.","volume":"43","author":"Indraccolo","year":"2010","journal-title":"Autoimmunity"},{"issue":"6","key":"2019111703285070400_B49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.","volume":"38","author":"Lu","year":"2010","journal-title":"Exp Hematol"},{"issue":"30","key":"2019111703285070400_B50","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells.","volume":"276","author":"Mayer","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111703285070400_B51","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4049\/jimmunol.135.4.2507","article-title":"Studies of interferon as a regulator of hematopoietic cell proliferation.","volume":"135","author":"Raefsky","year":"1985","journal-title":"J Immunol"},{"issue":"3","key":"2019111703285070400_B52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0609.2004.00275.x","article-title":"Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.","volume":"73","author":"Ito","year":"2004","journal-title":"Eur J Haematol"},{"issue":"8","key":"2019111703285070400_B53","first-page":"863","article-title":"Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells.","volume":"24","author":"Aman","year":"1996","journal-title":"Exp Hematol"},{"issue":"12","key":"2019111703285070400_B54","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood.V84.12.4142.bloodjournal84124142","article-title":"Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist.","volume":"84","author":"Aman","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2019111703285070400_B55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17425247.2.2.219","article-title":"Pegylated IFNs for chronic hepatitis C: an update.","volume":"2","author":"Grace","year":"2005","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"2019111703285070400_B56","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V89.2.483","article-title":"Thrombopoietin signal transduction in purified murine megakaryocytes.","volume":"89","author":"Drachman","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111703285070400_B57","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1.","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111703285070400_B58","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2007-12-125906","article-title":"Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes.","volume":"112","author":"Yamane","year":"2008","journal-title":"Blood"},{"key":"2019111703285070400_B59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000226080","article-title":"Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.","volume":"42","author":"Ludwig","year":"1985","journal-title":"Oncology"},{"issue":"29","key":"2019111703285070400_B60","doi-asserted-by":"crossref","first-page":"12097","DOI":"10.1073\/pnas.0900562106","article-title":"Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses.","volume":"106","author":"Joshi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"2019111703285070400_B61","doi-asserted-by":"crossref","first-page":"25051","DOI":"10.1074\/jbc.M109.030445","article-title":"Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses.","volume":"284","author":"Katsoulidis","year":"2009","journal-title":"J Biol Chem"},{"issue":"19","key":"2019111703285070400_B62","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1158\/0008-5472.CAN-04-4555","article-title":"Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.","volume":"65","author":"Katsoulidis","year":"2005","journal-title":"Cancer Res"},{"issue":"30","key":"2019111703285070400_B63","doi-asserted-by":"crossref","first-page":"21256","DOI":"10.1074\/jbc.M510644200","article-title":"JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells.","volume":"281","author":"Kim","year":"2006","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111703285070400_B64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jb\/mvp213","article-title":"Interferon-alpha induces the growth inhibition of human T-cell leukaemia line Jurkat through p38alpha and p38beta.","volume":"147","author":"Lee","year":"2010","journal-title":"J Biochem"},{"issue":"36","key":"2019111703285070400_B65","doi-asserted-by":"crossref","first-page":"27634","DOI":"10.1074\/jbc.M003170200","article-title":"The Rac1\/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins.","volume":"275","author":"Uddin","year":"2000","journal-title":"J Biol Chem"},{"issue":"7240","key":"2019111703285070400_B66","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo.","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"issue":"6","key":"2019111703285070400_B67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion.","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"},{"issue":"7299","key":"2019111703285070400_B68","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nature09135","article-title":"Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection.","volume":"465","author":"Baldridge","year":"2010","journal-title":"Nature"},{"issue":"3","key":"2019111703285070400_B69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri2726","article-title":"Awakening dormant haematopoietic stem cells.","volume":"10","author":"Trumpp","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2019111703285070400_B70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"14","key":"2019111703285070400_B71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703285070400_B72","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1994.12.11.2405","article-title":"Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.","volume":"12","author":"Salmon","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703285070400_B73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V67.2.275.275","article-title":"Treatment of multiple myeloma with recombinant alpha-interferon.","volume":"67","author":"Quesada","year":"1986","journal-title":"Blood"},{"issue":"6","key":"2019111703285070400_B74","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","article-title":"Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703285070400_B75","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis.","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111703285070400_B76","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111703285070400_B77","article-title":"Maintenance therapy by Glivec(R) and Pegasys(R) in patients with Philadelphia positive acute lymphocytic leukemia not eligible for hematopoietic stem cell transplantation [abstract].","volume":"110","author":"Rousselot","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111703285070400_B78","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111703285070400_B79","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111703285070400_B80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia: the Italian Cooperative Study Group on Chronic Myeloid Leukemia.","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703285070400_B81","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111703285070400_B82","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111703285070400_B83","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111703285070400_B84","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"2019111703285070400_B85","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703285070400_B86","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111703285070400_B87","first-page":"LBA-1","article-title":"Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial [abstract].","volume":"114","author":"Saglio","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111703285070400_B88","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/leu.2009.96","article-title":"Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.","volume":"23","author":"Visani","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111703285070400_B89","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome.","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111703285070400_B90","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome.","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2019111703285070400_B91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","article-title":"Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.","volume":"22","author":"Griesshammer","year":"2008","journal-title":"Blood Rev"},{"issue":"11","key":"2019111703285070400_B92","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111703285070400_B93","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111703285070400_B94","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111703285070400_B95","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.","volume":"121","author":"Butterfield","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019111703285070400_B96","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002770050434","article-title":"Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases.","volume":"77","author":"Ceretelli","year":"1998","journal-title":"Ann Hematol"},{"issue":"8607","key":"2019111703285070400_B97","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera.","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"8617","key":"2019111703285070400_B98","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0140-6736(88)92625-6","article-title":"Treatment of essential thrombocythaemia by alpha 2a interferon.","volume":"2","author":"Bellucci","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"2019111703285070400_B99","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138945011794815275","article-title":"Interferon Alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms: status and perspectives.","volume":"12","author":"Hasselbalch","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"20","key":"2019111703285070400_B100","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111703285070400_B101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00320164","article-title":"Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia.","volume":"58","author":"Barosi","year":"1989","journal-title":"Blut"},{"issue":"2","key":"2019111703285070400_B102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2009.07745.x","article-title":"PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM).","volume":"146","author":"Ianotto","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111703285070400_B103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01697629","article-title":"Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera.","volume":"66","author":"Hino","year":"1993","journal-title":"Ann Hematol"},{"issue":"8","key":"2019111703285070400_B104","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111703285070400_B105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone.","volume":"56","author":"Massaro","year":"1997","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111703285070400_B106","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.1994.tb04752.x","article-title":"Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha.","volume":"86","author":"Messora","year":"1994","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111703285070400_B107","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera: a report on molecular response patterns in seven patients in sustained complete hematological remission.","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"issue":"6","key":"2019111703285070400_B108","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"2019111703285070400_B109","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.leu.2404475","article-title":"Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera.","volume":"21","author":"Ishii","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"2019111703285070400_B110","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"2019111703285070400_B111","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/leu.2009.90","article-title":"Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.","volume":"23","author":"Silver","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111703285070400_B112","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon alpha in the treatment of polycythemia vera.","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111703285070400_B113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2019111703285070400_B114","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703285070400_B115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis.","volume":"130","author":"McMullin","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111703285070400_B116","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"issue":"6","key":"2019111703285070400_B117","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703285070400_B118","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"4 Pt 2","key":"2019111703285070400_B119","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/18\/4706\/1336300\/zh801811004706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/18\/4706\/1336300\/zh801811004706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T17:45:04Z","timestamp":1685987104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/18\/4706\/21384\/The-renaissance-of-interferon-therapy-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,5]]},"references-count":119,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,5,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-08-258772","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,5]]}}}